Compare FR & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FR | ARWR |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 8.0B |
| IPO Year | 1996 | 2009 |
| Metric | FR | ARWR |
|---|---|---|
| Price | $58.49 | $60.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $61.42 | ★ $81.50 |
| AVG Volume (30 Days) | 893.5K | ★ 1.9M |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ 1.87 | 0.22 |
| Revenue | ★ $727,076,000.00 | $16,142,321.00 |
| Revenue This Year | $11.58 | N/A |
| Revenue Next Year | $7.64 | N/A |
| P/E Ratio | ★ $31.26 | $276.86 |
| Revenue Growth | ★ 8.58 | N/A |
| 52 Week Low | $40.31 | $10.92 |
| 52 Week High | $64.01 | $76.76 |
| Indicator | FR | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 50.60 |
| Support Level | $56.87 | $54.02 |
| Resistance Level | $60.14 | $66.37 |
| Average True Range (ATR) | 1.34 | 3.06 |
| MACD | -0.03 | 0.66 |
| Stochastic Oscillator | 32.19 | 55.27 |
First Industrial Realty Trust Inc is a real estate investment trust that owns, manages, acquires, sells, develops, and redevelops industrial real estate. Through its fully integrated operating and investing platform, the company provides facilities and customer service to multinational corporations and regional firms that are essential for their supply chains. The company serves a diverse tenant base across various sectors, including e-commerce, logistics, transportation, manufacturing, retail, consumer services, food and beverage, building materials, wholesale goods, health services, and government.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.